ZEISS Ventures has invested in Maculaser, a Finnish medtech company developing temperature-controlled retinal laser therapy, through a funding round co-led with M2care. The investment will support clinical development of the company's personalized treatment for retinal diseases. Founded in 2020 and based on research from Aalto University, Maculaser has developed patented technology that provides real-time temperature control during laser treatment. The non-damaging approach activates natural cellular defence mechanisms, targeting affected retinal areas early to delay or prevent progression of age-related macular degeneration and diabetic maculopathy. The technology aims to shift retinal care from managing late-stage damage to proactive vision preservation, offering an outpatient procedure that integrates into regular eye care. Maculaser plans to bring the treatment into clinical practice to benefit millions of patients worldwide.

ZEISS Medical Technology has received approval from Mexico's COFEPRIS for two ophthalmic surgical devices: the ARTEVO 850 microscope and MICOR 700 lens removal device. Both technologies are compatible with ZEISS's latest cataract workflow systems. The ARTEVO 850 is a 3D heads-up ophthalmic microscope offering true colour imaging and a nearly 60% increase in depth of field. The MICOR 700 is the first handheld lens removal device with ultrasound-free operation, using ZEISS's non-ultrasonic lens extraction procedure to minimise risk to surrounding eye structures. The products will be showcased at the Mexican Congress of Ophthalmology in Monterrey from 30 May to 3 June 2026. ZEISS Medical Technology generated revenue of €2,066.1 million in fiscal year 2023/24.

Hypervision Surgical, a UK-based pioneer in real-time hyperspectral imaging for surgery, has raised £17 million in an oversubscribed Series A round led by Heal Capital. Angelini Ventures participated alongside IP Group and Daycrest, with Angelini Ventures Managing Director Tanja Dowe joining the board. The King's College London spin-out has developed the Hyperspectral Intelligence platform, which combines hyperspectral sensing with AI-driven analytics to provide real-time, quantitative insights into tissue physiology during surgery. The technology captures information beyond what conventional surgical cameras can perceive, potentially improving intraoperative decision-making and reducing complications. The funding will support commercial deployment, clinical adoption and development of next-generation hyperspectral sensing technology. The company's HYPERSNAP system is certified in the UK and cleared by the US FDA.